Jagsonpal Pharma Declares Financial Results for Q1

Aug. 25, 2010 - PRLog -- Jagsonpal Pharmaceuticals Limited, an integrated pharmaceuticals company headquartered in New Delhi, has posted excellent standalone results for the first quarter of financial year 2010-11 ended on June 2010 (Q1 FY 2010-11). As per the unaudited provisional standalone results, the income from operations has gone up to Rs. 4117 lacs for Q1 FY 2010-11 as compared to Rs. 3330 lacs during the corresponding quarter in the previous year. The Net Profit (PAT) too has gone up to Rs. 323.53 lacs for Q1 FY 2010-11 reflecting a growth of 115.64% over the previous corresponding quarter’s figure of Rs. 150.15 lacs.  

Further, the Board of Directors has also approved the audited results of the company for FY 2009-10. Motivated with the enthusiastic performance Jagsonpal has rewarded the shareholders with double dividend compared to FY 2008-09.

Earlier, during the financial year ended March 2010, a new state-of-the-art manufacturing facility of the company located at the excise free zone at IIE Pant Nagar (Uttarakhand), has started commercial operations. The company has invested Rs.25 crore to establish this unit.

Expansion of marketing strength, hike of stakes in cardiovascular and diabetic segment, establishment of new manufacturing facilities, launch of new products, enhanced penetration into rural and semi-urban markets and strong growth in the traditional products have been some of the factors responsible for the improved performance of the company.


About Jagsonpal Pharmaceuticals Limited

Founded in the year 1964, Jagsonpal Pharmaceuticals Limited is presently one among the leading pharmaceutical companies in India, ranked amongst top 100 in the industry comprising of about 28,000 players, to be specific with an annual turnover of Rs. 139 crore. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. It has a perennial presence in niche therapeutic segments like Women’s Helathcare, Nutraceuticals/Vitamin Suppliments, Cardiology, Diabetes, Antibiotics and Orthopedics.

The company has a judicious mix of drug formulations and Active Pharma Ingredients (APIs). Jagsonpal Pharma also has a state-of-the-art R&D Centre at Faridabad which is approved by the Department of Scientific & Industrial Research, Ministry of Science & Technology.

# # #

With a rich experience of over 14 years India News Communications Ltd. (INCL) commands an in-depth knowledge of all the domains of marketing communications industry namely Advertising, Public Relations and In-Film Promotion.